Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R A PEACOCK

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Gut|August 13, 2002
Relative contribution of mucosal injury and Helicobacter pylori in the development of gastroduodenal lesions in patients taking non-steroidal anti-inflammatory drugsC J Hawkey, J Naesdal, I Wilson, et al.
Alimentary Pharmacology & Therapeutics|August 6, 1998
Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug usersD Cullen, K D Bardhan, M Eisner, et al.
Alimentary Pharmacology & Therapeutics|June 26, 2001
Characteristics of patients with irritable bowel syndrome recruited from three sources: implications for clinical trialsG F Longstreth, C J Hawkey, E A Mayer, et al.
Lancet (London, England)|October 6, 1998
Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion PreventionC J Hawkey, Z Tulassay, L Szczepanski, et al.
Scandinavian Journal of Gastroenterology|October 9, 2003
An irritable bowel syndrome-specific symptom questionnaire: development and validationI K Wiklund, S Fullerton, C J Hawkey, et al.
BMJ (Clinical Research Ed.)|February 19, 1999
Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. The European Study GroupK D Bardhan, S Müller-Lissner, M A Bigard, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Gut|August 13, 2002
Relative contribution of mucosal injury and Helicobacter pylori in the development of gastroduodenal lesions in patients taking non-steroidal anti-inflammatory drugsC J Hawkey, J Naesdal, I Wilson, et al.
Alimentary Pharmacology & Therapeutics|August 6, 1998
Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug usersD Cullen, K D Bardhan, M Eisner, et al.
Alimentary Pharmacology & Therapeutics|June 26, 2001
Characteristics of patients with irritable bowel syndrome recruited from three sources: implications for clinical trialsG F Longstreth, C J Hawkey, E A Mayer, et al.
Lancet (London, England)|October 6, 1998
Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion PreventionC J Hawkey, Z Tulassay, L Szczepanski, et al.
Scandinavian Journal of Gastroenterology|October 9, 2003
An irritable bowel syndrome-specific symptom questionnaire: development and validationI K Wiklund, S Fullerton, C J Hawkey, et al.
BMJ (Clinical Research Ed.)|February 19, 1999
Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. The European Study GroupK D Bardhan, S Müller-Lissner, M A Bigard, et al.
Pageof 1